ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an
end-to-end commercial biopharmaceutical company dedicated to
manufacturing, marketing and developing specialty plasma-derived
biologics, today announced that it intends to offer shares of its
common stock for sale in an underwritten public offering. The
Company intends to grant the underwriters of the offering a 30-day
option to purchase up to an additional 15 percent of the number of
shares of common stock sold in connection with the offering. The
proposed offering is subject to market and other conditions, and
there can be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the
offering.
ADMA intends to use the net proceeds from this offering to
accelerate commercialization and production activities, complete
plasma center buildout and obtain FDA approvals, to conclude post
FDA marketing approval research and development projects, and for
working capital, capital expenditures and for general corporate
purposes.
Raymond James & Associates, Inc., Cantor Fitzgerald &
Co. and Mizuho Securities USA LLC are acting as joint book-running
managers of the proposed offering.
The securities described above are being offered by the Company
pursuant to a “shelf” registration statement on Form S-3 (File No.
333-256643) previously filed with the Securities and Exchange
Commission (“SEC”) and declared effective by the SEC on August 3,
2021. The preliminary prospectus supplement and the accompanying
prospectus relating to the offering will be filed with the SEC and
will be available on the SEC’s website at www.sec.gov. Electronic
copies of the preliminary prospectus supplement and the
accompanying prospectus relating to the offering may be obtained,
when available, from Raymond James & Associates, Inc.,
Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg,
Florida 33716, or by telephone at (800) 248-8863, or e-mail at
prospectus@raymondjames.com, or from Cantor Fitzgerald & Co.,
Attn: Capital Markets, 499 Park Avenue, 4th Floor, New York, New
York 10022 or by email at prospectus@cantor.com, or from Mizuho
Securities USA LLC, Attention: Equity Capital Markets, 1271 Avenue
of the Americas, 3rd Floor, New York, NY 10020, by email at
US-ECM@us.mizuho-sc.com, or by telephone at (212) 205-7600.
Before investing in the offering, you should read in their
entirety the preliminary prospectus supplement and its accompanying
prospectus to be filed with the SEC, and the other documents that
the Company has filed with the SEC that will be incorporated by
reference in the prospectus supplement and its accompanying
prospectus, which will provide more information about the Company
and the offering.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities described herein,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About ADMA Biologics, Inc.
(ADMA)
ADMA Biologics is an end-to-end commercial
biopharmaceutical company dedicated to manufacturing, marketing and
developing specialty plasma-derived biologics for the treatment of
immunodeficient patients at risk for infection and others at risk
for certain infectious diseases. ADMA currently manufactures and
markets three United States Food and Drug Administration
(FDA)-approved plasma-derived biologics for the treatment of immune
deficiencies and the prevention of certain infectious diseases:
BIVIGAM® (immune globulin intravenous, human) for the treatment of
primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin
intravenous, human – slra 10% liquid) for the treatment of PI; and
NABI-HB® (hepatitis B immune globulin, human) to provide enhanced
immunity against the hepatitis B virus. ADMA manufactures its
immune globulin products at its FDA-licensed plasma fractionation
and purification facility located in Boca Raton, Florida. Through
its ADMA BioCenters subsidiary, ADMA also operates as an
FDA-approved source plasma collector in the U.S., which provides a
portion of its blood plasma for the manufacture of its products.
ADMA’s mission is to manufacture, market and develop specialty
plasma-derived, human immune globulins targeted to niche patient
populations for the treatment and prevention of certain infectious
diseases and management of immune compromised patient populations
who suffer from an underlying immune deficiency, or who may be
immune compromised for other medical reasons. ADMA has received
U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and
10,259,865 and European Patent No. 3375789, among others, related
to certain aspects of its products and product candidates. For more
information, please visit www.admabiologics.com.
Cautionary Note Regarding
Forward-Looking Statements
This press release contains “forward-looking
statements” pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995, about ADMA Biologics,
Inc. (“we,” “our” or the “Company”). Forward-looking statements
include, without limitation, any statement that may predict,
forecast, indicate, or imply future results, performance or
achievements, and may contain such words as “estimate,” “project,”
“intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,”
“expect,” “believe,” “will,” “is likely,” “will likely,” “should,”
“could,” “would,” “may,” or, in each case, their negative, or words
or expressions of similar meaning. These forward-looking statements
include statements about the offering, ADMA’s intention to grant
the underwriters a 30-day option to purchase additional shares in
the offering, and ADMA’s intended use of proceeds generated from
the offering. Actual events or results may differ materially from
those described in this document due to a number of important
factors. Current and prospective security holders are cautioned
that there also can be no assurance that the forward-looking
statements included in this press release will prove to be
accurate. Except to the extent required by applicable laws or
rules, ADMA does not undertake any obligation to update any
forward-looking statements or to announce revisions to any of the
forward-looking statements. Forward-looking statements are subject
to many risks, uncertainties and other factors that could cause our
actual results, and the timing of certain events, to differ
materially from any future results expressed or implied by the
forward-looking statements, including, but not limited to, risks
and uncertainties related to market conditions and satisfaction of
customary closing conditions related to the public offering and the
risks and uncertainties described in our filings with the U.S.
Securities and Exchange Commission, including our most recent
reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.
COMPANY CONTACT:
Skyler BloomSenior Director, Corporate Strategy
and Business Development | 201-478-5552 | sbloom@admabio.com
INVESTOR RELATIONS
CONTACT:Michelle Pappanastos Senior Managing Director,
Argot Partners | 212-600-1902 | michelle@argotpartners.com
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Apr 2024 to May 2024
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From May 2023 to May 2024